{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:42:52Z","timestamp":1761871372089,"version":"build-2065373602"},"reference-count":28,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100006436","name":"Celgene","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006436","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006436","name":"Celgene","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006436","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1016\/j.clml.2019.07.002","type":"journal-article","created":{"date-parts":[[2019,7,17]],"date-time":"2019-07-17T19:54:12Z","timestamp":1563393252000},"page":"776-783","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["A New Salvage Regimen for Aggressive Lymphomas Based on Gemcitabine, Rituximab, and Oxaliplatin Followed by Lenalidomide (GROC-Rev)"],"prefix":"10.1016","volume":"19","author":[{"given":"Fernando","family":"Cabanillas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noridza","family":"Rivera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mirelis","family":"Acosta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wandaly","family":"Pardo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pedro","family":"Solivan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caroline","family":"Rivera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Idalia","family":"Liboy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"15 suppl","key":"10.1016\/j.clml.2019.07.002_bib1","doi-asserted-by":"crossref","first-page":"8530","DOI":"10.1200\/jco.2008.26.15_suppl.8530","article-title":"GROC (gemcitabine, rituximab, oxaliplatin combination) plus pegfilgrastim is less toxic and as active as DHAP and ESHAP for relapsed aggressive non-Hodgkin\u2019s lymphoma (NHL)","volume":"26","author":"Cabanillas","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2019.07.002_bib2","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1111\/j.1600-0609.2007.00996.x","article-title":"GEMOX-R regimen is a highly effective salvage regimen in patients with refractory\/relapsing diffuse large-cell lymphoma: a phase II study","volume":"80","author":"Lopez","year":"2008","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.clml.2019.07.002_bib3","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1093\/annonc\/mdm133","article-title":"Rituximab, gemcitabine and oxaliplatin: an effective salvage regimen for patients with relapsed or refractory B-cell lymphoma not candidates for high-dose therapy","volume":"18","author":"El Gnaoui","year":"2007","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2019.07.002_bib4","doi-asserted-by":"crossref","first-page":"4952","DOI":"10.1200\/JCO.2007.15.3429","article-title":"Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin\u2019s lymphoma","volume":"26","author":"Wiernik","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2019.07.002_bib5","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1200\/JCO.2017.72.6984","article-title":"Lenalidomide maintenance compared with placebo in responding elderly patients with diffuse large B-cell lymphoma treated with first-line rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone","volume":"35","author":"Thieblemont","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2019.07.002_bib6","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1200\/JCO.2014.55.5714","article-title":"Lenalidomide combined with R-CHOP overcomes negative prognostic impact of non\u2013germinal center B-cell phenotype in newly diagnosed diffuse large B-cell lymphoma: a phase II study","volume":"33","author":"Nowakowski","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2019.07.002_bib7","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.mvr.2005.01.002","article-title":"Orally administered lenalidomide (CC-5013) is anti-angiogenic in\u00a0vivo and inhibits endothelial cell migration and Akt phosphorylation in\u00a0vitro","volume":"69","author":"Dredge","year":"2005","journal-title":"Microvasc Res"},{"key":"10.1016\/j.clml.2019.07.002_bib8","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1124\/jpet.102.048496","article-title":"Enhancement of cytokine production and AP-1 transcriptional activity in T cells by thalidomide-related immunomodulatory drugs","volume":"305","author":"Schafer","year":"2003","journal-title":"J\u00a0Pharmacol Exp Ther"},{"key":"10.1016\/j.clml.2019.07.002_bib9","doi-asserted-by":"crossref","first-page":"4650","DOI":"10.1158\/1078-0432.CCR-07-4405","article-title":"Lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells","volume":"14","author":"Wu","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2019.07.002_bib10","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1182\/blood.V98.1.210","article-title":"Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma","volume":"98","author":"Davies","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.07.002_bib11","doi-asserted-by":"crossref","first-page":"2943","DOI":"10.1182\/blood.V96.9.2943","article-title":"Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy","volume":"96","author":"Hideshima","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.07.002_bib12","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1200\/JCO.1999.17.4.1244","article-title":"Report of an international workshop to standardize response criteria for non-Hodgkin\u2019s lymphomas. NCI Sponsored International Working Group","volume":"17","author":"Cheson","year":"1999","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2019.07.002_bib13","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1056\/NEJM198706113162401","article-title":"High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin\u2019s lymphoma","volume":"316","author":"Philip","year":"1987","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2019.07.002_bib14","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1007\/s00277-014-2271-1","article-title":"Prognosis of patients with diffuse large B cell lymphoma not reaching complete response or relapsing after frontline chemotherapy or immunochemotherapy","volume":"94","author":"Rovira","year":"2015","journal-title":"Ann Hematol"},{"key":"10.1016\/j.clml.2019.07.002_bib15","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.exphem.2017.09.002","article-title":"Lenalidomide modulates gene expression in human ABC-DLBCL cells by regulating IKAROS interaction with an intronic control region of SPIB","volume":"56","author":"Solomon","year":"2017","journal-title":"Exp Hematol"},{"key":"10.1016\/j.clml.2019.07.002_bib16","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1111\/bjh.14866","article-title":"Activity of lenalidomide in mantle cell lymphoma can be explained by NK cell-mediated cytotoxicity","volume":"179","author":"Hagner","year":"2017","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2019.07.002_bib17","doi-asserted-by":"crossref","first-page":"689","DOI":"10.2174\/1568009616666160408145741","article-title":"Mechanistic and clinical aspects of lenalidomide treatment for chronic lymphocytic leukemia","volume":"16","author":"Riches","year":"2016","journal-title":"Curr Cancer Drug Targets"},{"key":"10.1016\/j.clml.2019.07.002_bib18","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1177\/2040620716652861","article-title":"A\u00a0comprehensive review of lenalidomide in B-cell non-Hodgkin lymphoma","volume":"7","author":"Arora","year":"2016","journal-title":"Ther Adv Hematol"},{"key":"10.1016\/j.clml.2019.07.002_bib19","doi-asserted-by":"crossref","first-page":"19","DOI":"10.4161\/15384047.2014.972828","article-title":"Structural studies reveal thalidomide\u2019s mechanism of action and clinical effects: crystal clear or clearly complexed?","volume":"16","author":"Ley","year":"2015","journal-title":"Cancer Biol Ther"},{"key":"10.1016\/j.clml.2019.07.002_bib20","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1182\/blood.V60.3.693.693","article-title":"IMVP-16: an effective regimen for patients with lymphoma who have relapsed after initial combination chemotherapy","volume":"60","author":"Cabanillas","year":"1982","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.07.002_bib21","doi-asserted-by":"crossref","first-page":"4184","DOI":"10.1200\/JCO.2010.28.1618","article-title":"Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era","volume":"28","author":"Gisselbrecht","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2019.07.002_bib22","doi-asserted-by":"crossref","first-page":"4127","DOI":"10.1158\/1078-0432.CCR-16-2818","article-title":"A\u00a0Phase 2\/3 multicenter, randomized, open-label study to compare the efficacy and safety of lenalidomide versus investigator\u2019s choice in patients with relapsed or refractory diffuse large B-cell lymphoma","volume":"23","author":"Czuczman","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2019.07.002_bib23","doi-asserted-by":"crossref","first-page":"5058","DOI":"10.1002\/cncr.26135","article-title":"Higher response to lenalidomide in relapsed\/refractory diffuse large B-cell lymphoma in nongerminal center B-cell\u2013like than in germinal center B-cell\u2013like phenotype","volume":"117","author":"Hernandez-Ilizaliturri","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2019.07.002_bib24","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1634\/theoncologist.2016-0103","article-title":"Lenalidomide in relapsed or refractory diffuse large b-cell lymphoma: is it a valid treatment option?","volume":"21","author":"Mondello","year":"2016","journal-title":"Oncologist"},{"key":"10.1016\/j.clml.2019.07.002_bib25","first-page":"10705","article-title":"Lenalidomide alone or in combination\u00a0with\u00a0chemotherapy treatment for subtypes of diffuse large B cell lymphoma: a\u00a0systematic review and meta-analysis","volume":"8","author":"Fang","year":"2015","journal-title":"Int J Clin Exp Med"},{"key":"10.1016\/j.clml.2019.07.002_bib26","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1182\/blood.V71.1.117.117","article-title":"Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP)","volume":"71","author":"Velasquez","year":"1988","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.07.002_bib27","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1200\/JCO.1994.12.6.1169","article-title":"ESHAP\u2014an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study","volume":"12","author":"Velasquez","year":"1994","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2019.07.002_bib28","doi-asserted-by":"crossref","first-page":"3684","DOI":"10.1182\/blood-2003-11-3911","article-title":"Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma","volume":"103","author":"Kewalramani","year":"2004","journal-title":"Blood"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265019301569?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265019301569?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:33:26Z","timestamp":1761870806000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265019301569"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":28,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["S2152265019301569"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2019.07.002","relation":{},"ISSN":["2152-2650"],"issn-type":[{"type":"print","value":"2152-2650"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A New Salvage Regimen for Aggressive Lymphomas Based on Gemcitabine, Rituximab, and Oxaliplatin Followed by Lenalidomide (GROC-Rev)","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2019.07.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}